IL256224B - Combined therapy for cancer treatment - Google Patents

Combined therapy for cancer treatment

Info

Publication number
IL256224B
IL256224B IL256224A IL25622417A IL256224B IL 256224 B IL256224 B IL 256224B IL 256224 A IL256224 A IL 256224A IL 25622417 A IL25622417 A IL 25622417A IL 256224 B IL256224 B IL 256224B
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination therapy
therapy
combination
Prior art date
Application number
IL256224A
Other languages
English (en)
Hebrew (he)
Other versions
IL256224A (en
Inventor
Koenig Scott
Bonvini Ezio
Marc WIGGINGTON Jon
Bharat Pandya Naimish
Joseph LECHLEIDER Robert
Original Assignee
Macrogenics Inc
Koenig Scott
Bonvini Ezio
Marc WIGGINGTON Jon
Bharat Pandya Naimish
Joseph LECHLEIDER Robert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Koenig Scott, Bonvini Ezio, Marc WIGGINGTON Jon, Bharat Pandya Naimish, Joseph LECHLEIDER Robert filed Critical Macrogenics Inc
Publication of IL256224A publication Critical patent/IL256224A/en
Publication of IL256224B publication Critical patent/IL256224B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL256224A 2015-06-12 2017-12-10 Combined therapy for cancer treatment IL256224B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562175039P 2015-06-12 2015-06-12
US201562211109P 2015-08-28 2015-08-28
US201562242640P 2015-10-16 2015-10-16
PCT/US2016/036608 WO2016201051A1 (en) 2015-06-12 2016-06-09 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
IL256224A IL256224A (en) 2018-02-28
IL256224B true IL256224B (en) 2022-06-01

Family

ID=57504564

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256224A IL256224B (en) 2015-06-12 2017-12-10 Combined therapy for cancer treatment

Country Status (20)

Country Link
US (3) US11078279B2 (enExample)
EP (1) EP3307240A4 (enExample)
JP (2) JP2018516966A (enExample)
KR (1) KR20180021774A (enExample)
CN (2) CN116898963A (enExample)
AU (2) AU2016276706B2 (enExample)
BR (1) BR112017026704A2 (enExample)
CA (1) CA2988602A1 (enExample)
CL (1) CL2017003131A1 (enExample)
GE (2) GEAP202114669A (enExample)
HK (1) HK1247129A1 (enExample)
IL (1) IL256224B (enExample)
MX (1) MX2017016071A (enExample)
MY (1) MY194621A (enExample)
PH (1) PH12017502270A1 (enExample)
RU (1) RU2733315C2 (enExample)
TW (1) TWI870335B (enExample)
UA (1) UA125207C2 (enExample)
WO (1) WO2016201051A1 (enExample)
ZA (1) ZA201708225B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2720368C (en) * 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
TWI870335B (zh) * 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
KR102761886B1 (ko) 2015-07-30 2025-02-06 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
US11174315B2 (en) * 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
PE20190576A1 (es) 2016-09-29 2019-04-22 Beijing Hanmi Pharmaceutical Co Ltd Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas
MX2019005858A (es) * 2016-11-18 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019195621A1 (en) * 2018-04-04 2019-10-10 Immutics, Inc. Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
JP2021527714A (ja) * 2018-06-20 2021-10-14 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｄ−１抗体及びその使用
MY208487A (en) * 2019-08-02 2025-05-13 Cttq Akeso Shanghai Biomed Tech Co Ltd Anti-pd-1 antibody and medical use thereof
US12151004B2 (en) * 2020-01-31 2024-11-26 University Of Saskatchewan Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US20230158016A1 (en) * 2020-03-16 2023-05-25 H Lee Moffitt Cancer Center And Research Institute, Inc. Delta opioid receptor antagonists reprogram immunosuppressive microenvironment to boost immunotherapy
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449736A (en) 1981-12-16 1984-05-22 Dresser Industries, Inc. Releasable tubing string connector
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0359096B1 (en) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0846571B1 (en) 1996-12-04 2001-04-11 Agfa-Gevaert N.V. Method for the formation of an improved heat mode image
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
BR0311471A (pt) 2002-05-30 2007-04-27 Macrogenics Inc anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
CA2499995A1 (en) 2002-09-23 2004-04-01 Macrogenics, Inc. Compositions and methods for treatment of herpesvirus infections
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7112439B2 (en) 2003-01-09 2006-09-26 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
CN104104517B (zh) 2004-10-15 2017-11-07 弗里塞恩公司 一次性密码验证的方法和系统
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2006066078A2 (en) 2004-12-15 2006-06-22 Magrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
SI1919503T1 (sl) 2005-08-10 2015-02-27 Macrogenics, Inc. Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
KR101599735B1 (ko) 2007-06-21 2016-03-07 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101951959A (zh) 2007-11-30 2011-01-19 百时美施贵宝公司 抗b7h4单克隆抗体-药物缀合物和使用方法
CA2720368C (en) * 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8876892B2 (en) 2010-04-21 2014-11-04 Medtronic, Inc. Prosthetic heart valve delivery system with spacing
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
CN104080804B (zh) 2011-05-21 2017-06-09 宏观基因有限公司 去免疫化的血清结合结构域及其延长血清半衰期的用途
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
US20150290316A1 (en) 2012-10-02 2015-10-15 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US10077305B2 (en) * 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
FI3083686T4 (fi) * 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI870335B (zh) * 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
KR102761886B1 (ko) 2015-07-30 2025-02-06 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법

Also Published As

Publication number Publication date
AU2016276706B2 (en) 2021-05-13
GEAP202114669A (en) 2021-03-10
BR112017026704A2 (pt) 2018-08-28
CN116898963A (zh) 2023-10-20
TWI870335B (zh) 2025-01-21
EP3307240A1 (en) 2018-04-18
RU2018100424A3 (enExample) 2019-11-26
EP3307240A4 (en) 2018-12-19
US20220041725A1 (en) 2022-02-10
US20180298100A1 (en) 2018-10-18
CA2988602A1 (en) 2016-12-15
RU2733315C2 (ru) 2020-10-01
TW201709929A (zh) 2017-03-16
MX2017016071A (es) 2018-02-21
ZA201708225B (en) 2020-09-30
JP2018516966A (ja) 2018-06-28
AU2016276706A2 (en) 2018-06-14
RU2018100424A (ru) 2019-07-15
GEP20217271B (en) 2021-07-12
HK1247129A1 (zh) 2018-09-21
IL256224A (en) 2018-02-28
AU2016276706A1 (en) 2018-01-04
US11078279B2 (en) 2021-08-03
PH12017502270A1 (en) 2018-06-11
CN107708666A (zh) 2018-02-16
MY194621A (en) 2022-12-07
AU2021212139A1 (en) 2021-08-26
JP2022050522A (ja) 2022-03-30
UA125207C2 (uk) 2022-02-02
CL2017003131A1 (es) 2018-05-25
WO2016201051A1 (en) 2016-12-15
US20250215088A1 (en) 2025-07-03
KR20180021774A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
IL291844B1 (en) smc combined therapy for cancer treatment
IL256224B (en) Combined therapy for cancer treatment
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL258521A (en) Combination of treatments for cancer treatment
IL267795A (en) Combined treatment for cancer
IL255060A0 (en) Combined treatment for cancer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
SG11201609770TA (en) Combination therapies for the treatment of cancer
IL259996A (en) Combinations for cancer treatment
EP3258965A4 (en) Combination therapy for cancer treatment
GB201500374D0 (en) Combined preparations for the treatment of cancer
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
LT3622953T (lt) Kombinuotas vėžio gydymas
IL257073A (en) Combined therapies for cancer treatment
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3185884A4 (en) Combination therapy for treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL258494A (en) Rational combined therapy for cancer treatment
IL266993A (en) Combined therapy for cancer treatment
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL253642A0 (en) Combined treatment for cancer
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer